Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Dupixent approved in China as the first-ever biologic medicine for patients ...
Dupixent approved in China as the first biologic for COPD, following EU approval. Based on phase 3 studies, Dupixent significantly reduced exacerbations, improved lung function, and quality of life. COPD is a priority in China's Healthy China 2030 plan. Dupixent is now approved in four indications in China.
Dupixent approved in China as the first-ever biologic medicine for patients
Dupixent approved in China for COPD, reducing exacerbations, improving lung function, and enhancing quality of life in phase 3 studies.
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
The article discusses the importance of summarizing content accurately and concisely, focusing on retaining original expressions while ensuring clarity.
Struggling 2Seventy scraps a key cancer study
2Seventy bio halts enrollment in a key multiple myeloma study for its therapy Abecma to save $80 million, aiming for financial break-even next year. Despite this, Abecma shows growth, with U.S. revenue expected to rise 30% in Q3. The decision reflects an improved treatment landscape for newly diagnosed patients, reducing eligible participants.
Related Clinical Trials:
Amgen claims success for two immune drugs, but results underwhelm Wall Street
Amgen's Phase 3 results for rocatinlimab in atopic dermatitis and Uplizna in myasthenia gravis were met with skepticism by analysts, who noted rocatinlimab's underwhelming efficacy and safety concerns, while Uplizna's potential as a second-line treatment was seen as sizable but not a threat to market leaders.
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In ...
Regeneron Pharmaceuticals' P/E, P/B, and P/S ratios are lower than industry averages, suggesting potential undervaluation. High ROE, EBITDA, and gross profit indicate strong profitability, but low revenue growth raises concerns about future performance.
Amgen's Drugs Show Promise in Phase 3 Trials
Amgen's Phase 3 trials for uplizna and rocatinlimab met key endpoints, potentially expanding treatment options and revenue growth. Uplizna targets CD19 to improve myasthenia gravis symptoms, while rocatinlimab shows promise in treating atopic dermatitis. Amgen also won a legal battle against Regeneron, allowing Pavblu's development. Wall Street rates AMGN with a Moderate Buy consensus, projecting 2.54% upside potential.
Regeneron's Eylea biosimilar fight heats up after court ruling
Regeneron shares dropped 5% after a judge denied its request to block Amgen from launching a biosimilar of its drug Eylea, called Pavblu. This ruling contrasts with previous injunctions granted by the same judge against other biosimilars, suggesting Pavblu may not infringe on Regeneron's patent. Regeneron has filed an appeal.
Biotechnology Market Outlook: Growth, Share, Value, Size, and Insights
The biotechnology market, valued at USD 1023.92 Million in 2022, is projected to reach USD 10129.16 Billion by 2030 with a CAGR of 29.00%. Driven by personalized medicine, R&D advancements, and investments, key players like Roche and Thermo Fisher Scientific Inc. are leading innovation. Segmented by technology, application, and end-user, the market spans healthcare, agriculture, and industrial biotechnology, among others.
© Copyright 2024. All Rights Reserved by MedPath